Leap Therapeutics Announces Encouraging Data from TRX518 Phase 1 in Immunosuppressive Cell Reduction (MCUR)
Tweet Send to a Friend
Leap Therapeutics, Inc. announced the presentation of data from its Phase 1 clinical trial of TRX518 in patients with advanced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
